Gufic Biosciences Management Guidance Tracker

Management expects the Indore facility to achieve EBITDA breakeven by Q4 FY26, with margin-accretive operations from FY27 onwards.

As Indore utilization exceeds 50%, EBITDA margin expected to rise from current 16% to 19%, and to 20-21% at >75% utilization.

At 70-80% capacity utilization, Indore can generate ₹750-800 crore in revenue, implying significant upside from current run-rate.

GLP-1 contract manufacturing with Hetero expected to start contributing revenue from Q1 FY27, post patent expiry in March 2026.

Management guided a minimum 15% topline growth for FY27, with potential upside to 20% if positive factors materialize.

Total borrowings (including working capital) of ~₹350-360 crore expected to reduce to ~₹300 crore in two years, with no major capex planned.

EU audit completed in December 2025; certificate expected by March or April, enabling regulated market exports from Q4/Q1.

Licensing deal with a Canadian company for dermal fillers; product launch expected in June-July to complement botox portfolio.